Open AccessHypersensitivity and Infusion-Site Adverse Events with Intravenous Fosaprepitant after Anthracycline-Containing Chemotherapy: A Retrospective Study
Author(s) -
Ralph V. Boccia,
Robert B. Geller,
Neil J. Clendeninn,
Thomas Ottoboni
Publication year - 2018
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2018-0662
Subject(s) - medicine , anthracycline , adverse effect , retrospective cohort study , chemotherapy , anesthesia , oncology , cancer , breast cancer
Fosaprepitant, an intravenous neurokinin-1 receptor antagonist for chemotherapy-induced nausea and vomiting, contains polysorbate 80, which is associated with infusion-site adverse events (ISAEs) and hypersensitivity systemic reactions (HSRs). This study investigated ISAEs/HSRs following fosaprepitant with anthracycline-containing chemotherapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom